期刊文献+

输注体外活化的自身淋巴细胞治疗晚期恶性肿瘤 被引量:2

BIOTHERAPY OF ADVANCED CANCER BY INFUSION OF IN VITRO ACTIVATED AUTOLYMPHOCYTES
原文传递
导出
摘要 自身淋巴细胞生物学疗法是一种可以门诊施行的治疗晚期恶性肿瘤的过继免疫疗法。其主要程序是输注体外用抗CD3单克隆抗体等活化的,用甲氰咪胍和低剂量γ射线等去除或抑制T抑制细胞活性的自身淋巴细胞。病人同时服用甲氰咪胍以去除或抑制体内T抑制细胞的活性。作者共治疗患者65例,217人次,除10例18人次在回输时有轻微类似输液反应的寒颤伴暂时的轻度体温升高外,未见其它毒性反应。对其中37例输注治疗3次以上的病人,进行临床疗效分析,缓解率(CR+PR)为24%,有效率(CR+PR+MR)为51%。自身淋巴细胞生物学疗法疗效与文献报道的LAK疗法相似,但费用低廉,副作用和毒性较低。 AbstractAutolymphocyte biotherapy is an adoptive cellular therapy based upon the infusion of autolo-gous lymphocytes that have been activated in vitro by anti-CD3 monoclonal antibody and depletedof suppressor T cells by cimetidine,indomethacin and low dose of γ irradiation. The patients alsoreceive oral cimetidine to block suppressor T cell activity in vivo. Sixty five patients received 217autolymphocyte infusions and toxicity was minimal with transient fever and chill accompanying 18ifusions.The efficacy of treatment in patients received more than 3 infusions were evaluated.In37 evaluable patients,the response rate(CR +PR)was 24%(9/37 ).As the side reactions aremild,the treatment can be done on an outpatient basis.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 1995年第6期464-466,共3页 Chinese Journal of Oncology
基金 河南省科委科技攻关
  • 相关文献

同被引文献16

  • 1华锦明,郑祖根,徐庚达.骨转移瘤肿瘤浸润淋巴细胞过继免疫治疗的临床研究[J].中华肿瘤杂志,1994,16(3):203-206. 被引量:7
  • 2刘树铮,刘伟宏.低剂量辐射刺激作用的实验研究[J].中华放射医学与防护杂志,1989,9(4):247-250. 被引量:12
  • 3曹世龙.肿瘤学新技术与新理论[M].上海科技教育出版社,1997.259.
  • 4刘树铮.低水平辐射兴奋效应研究进展[J].国外医学:放射医学核医学分册,1996,20:219-210.
  • 5Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997, 89 : 1845-1853.
  • 6Georgopoulos NT, Steele LP, Thonrson MJ, et al. A novel mechanism of CD40-indueed apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ, 2006, 13:1789-1801.
  • 7Georgopoulos NT, Merrick A, Scott N, et al. CIMO-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Caner, 2007, 121:1373.
  • 8Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CIM0 ligand (CD154) and its endogenous expression in human breast cancer, Clin Cancer Res, 2001,7:691-703.
  • 9Butterfield LH, Palucka AK, Britten CM, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res, 2011, 17:3064-3076.
  • 10Morgan G, Ward R, Barton M. The contribution of cytotoxic chetmtherapy to 5-year survival in adult malignancies. Clin Oncol (R Coil Radiol), 2004, 16:549-560.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部